BLA 761069 · Astrazeneca Uk LTD
Imfinzi
Durvalumab · Injection · Programmed Death Ligand-1 Blocker
NovelBreakthrough therapyAccelerated approvalPriority reviewOrphanLast checked: Nov 19, 2026Latest source record: Nov 13, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2017
May 1, 2017
Approved uses
18
Original approval plus efficacy supplements
Registered trials
832
107 Phase 3, 174 recruiting
FAERS reports
21,581
20,621 serious, 6,844 with death reported
AI brief across all sources
Written by Claude (Anthropic's AI) from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Aug 31, 2026.
IMFINZI is a programmed death-ligand 1 (PD-L1) blocking antibody indicated: • in combination with platinum-containing chemotherapy as neoadjuvant treatment, followed by IMFINZI continued as a single agent as adjuvant treatment after surgery, for the treatment of adult patients with resectable (tumors ≥ 4 cm and/or node positive) non-small cell lung cancer (NSCLC) and no known epidermal growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase (ALK) rearrangements. ( 1.1 ) • as a single agent, for the treatment of adult patients with unresectable, Stage III NSCLC whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.1 ) • in combination with tremelimumab-actl and platinum-based chemotherapy, for the treatment of adult patients with metastatic NSCLC with no sensitizing EGFR mutations or ALK genomic tumor aberrations. ( 1.1 ) • as a single agent, for the treatment of adult patients with limited-stage small cell lung cancer (LS-SCLC) whose disease has not progressed following concurrent platinum-based chemotherapy and radiation therapy. ( 1.2 ) • in combination with etoposide and either carboplatin or cisplatin, as first-line treatment of adult patients with extensive-stage small cell lung cancer (ES-SCLC). ( 1.2 ) • in combination with gemcitabine and cisplatin, as treatment of adult patients with locally advanced or metastatic biliary tract cancer (BTC). ( 1.3 ) • in combination with tremelimumab-actl, for the treatment of adult patients with unresectable hepatocellular carcinoma (uHCC). ( 1.4 ) • in combination with carboplatin and paclitaxel followed by IMFINZI as a single agent, for the treatment of adult patients with primary advanced or recurrent endometrial cancer that is mismatch repair deficient...
Mechanism: Expression of programmed cell death ligand-1 (PD-L1) can be induced by inflammatory signals (e.g., IFN-gamma) and can be expressed on both tumor cells and tumor-associated immune cells in the tumor microenvironment. PD-L1 blocks T-cell function and activation through interaction with PD-1 and CD80 (B7.1). By binding to its receptors, PD-L1 reduces cytotoxic T-cell activity, proliferation, and cytokine production. Durvalumab is a human immunoglobulin G1 kappa (IgG1κ) monoclonal antibody that binds to PD-L1 and blocks the interaction of PD-L1 with PD-1 and CD80 (B7.1). Blockade of PD-L1/PD-1...
Therapeutic areas: Kidney and urology
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Nov 13, 2026 Supplement 59 · Efficacy · priority review LabelMedication Guide
- May 28, 2026 Supplement 53 · Efficacy LetterLabelMedication Guide
- Nov 25, 2025 Supplement 52 · Efficacy · priority review Breakthrough therapyOrphanLetterLabel
- Mar 28, 2025 Supplement 50 · Efficacy · priority review LabelLetter
- Feb 28, 2025 Supplement 51 · Efficacy LabelLetter
- Dec 4, 2024 Supplement 49 · Efficacy · priority review Breakthrough therapyOrphanLabelLetter
- Aug 15, 2024 Supplement 43 · Efficacy LetterLabel
- Jun 14, 2024 Supplement 45 · Efficacy OrphanLabelLetter
- Nov 10, 2022 Supplement 33 · Efficacy LabelLetter
- Oct 21, 2022 Supplement 36 · Efficacy · priority review OrphanLetterLabel
- Sep 2, 2022 Supplement 35 · Efficacy · priority review OrphanLabelLetter
- Feb 19, 2021 Supplement 29 · Efficacy · priority review LetterLabel
- Nov 18, 2020 Supplement 23 · Efficacy · priority review LabelLetter
- Nov 18, 2020 Supplement 24 · Efficacy · priority review LabelLetter
- Mar 27, 2020 Supplement 18 · Efficacy · priority review LabelLetter
- Jul 19, 2019 Supplement 13 · Efficacy LabelLetter
- Feb 16, 2018 Supplement 2 · Efficacy · priority review Breakthrough therapyLabelLetter
- May 1, 2017 Original approval · Type 1 - New Molecular Entity · priority review NovelAccelerated approvalLabelLetterReview
1 products under this application
- IMFINZI · DURVALUMAB 50MG/ML · INJECTABLE, INJECTION · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Durvalumab" as an intervention, any sponsor and status, largest first.
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast CancerPivotal-lookingRecruiting
National Cancer Institute (NCI)NIH
NCT06058377 · 3,680 participants (planned) · Start Nov 27, 2023 · Primary completion May 31, 2032
Drug: Cyclophosphamide; Doxorubicin and 2 more · For: Anatomic Stage II Breast Cancer AJCC v8; Anatomic Stage III Breast Cancer AJCC v8; HER2-Negative Breast Carcinoma and 1 more
Sites: Birmingham, Alabama; Anchorage, Alaska; Tucson, Arizona · 565 sites in all
- A Phase III Randomised Study to Evaluate Dato-DXd and Durvalumab for Neoadjuvant/Adjuvant Treatment of Triple-Negative or Hormone Receptor-low/HER2-negative Breast CancerPivotal-lookingActive, not recruiting
AstraZenecaAstraZeneca (AZN)
NCT06112379 · 1,902 participants · Start Nov 14, 2023 · Primary completion Nov 20, 2028
Drug: Dato-DXd; Durvalumab and 8 more · For: Breast Cancer
Sites: Daphne, Alabama; Prescott, Arizona; Jonesboro, Arkansas · 283 sites in all
- Renal Adjuvant MultiPle Arm Randomised TrialPivotal-lookingRecruiting
University College, LondonAcademic, hospital or other
NCT03288532 · 1,750 participants (planned) · Start Jul 19, 2018 · Primary completion Jul 1, 2024
Drug: Durvalumab; Tremelimumab · For: Renal Cell Carcinoma
Sites: Aberdeen, United Kingdom; Bangor, United Kingdom; Bournemouth, United Kingdom · 35 sites in all
The Netherlands Cancer InstituteAcademic, hospital or other
NCT02925234 · 1,550 participants (planned) · Start Aug 2016 · Primary completion Sep 2027
Drug: Panitumumab; Olaparib and 35 more · For: Cancer; Tumors; Neoplasm and 1 more
Sites: Alkmaar, Netherlands; Almelo, Netherlands; Amersfoort, Netherlands · 36 sites in all
- The Effect of Serum Ferritin in irAERecruiting
Tianjin Medical University Cancer Institute and HospitalAcademic, hospital or other
NCT06702566 · 1,500 participants (planned) · Start Jul 4, 2024 · Primary completion Jul 16, 2026
Drug: PD-1 and PD-L1 inhibitor; Targeted drugs and 1 more · For: Immune-related Adverse Event; Malignant Solid Tumors; Acute Leukemia and 1 more
Sites: Tianjin, China
- SAFIR02_Breast - Efficacy of Genome Analysis as a Therapeutic Decision Tool for Patients With Metastatic Breast CancerPivotal-lookingActive, not recruiting
UNICANCERAcademic, hospital or other
NCT02299999 · 1,460 participants · Start Apr 7, 2014 · Primary completion Dec 2022
Drug: AZD2014; AZD4547 and 17 more · For: Metastatic Breast Cancer
Sites: Angers, France; Avignon, France; Bordeaux, France · 25 sites in all
- Double Blind Placebo Controlled Controlled Study of Adjuvant MEDI4736 In Completely Resected NSCLCPivotal-lookingCompleted
Canadian Cancer Trials GroupResearch network
NCT02273375 · 1,415 participants · Start Feb 24, 2015 · Primary completion Jul 23, 2025
Drug: MEDI4736; Placebo · For: Non-Small Cell Lung Cancer
Sites: Gilbert, Arizona; Los Angeles, California; Denver, Colorado · 271 sites in all
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- death4,160
- malignant neoplasm progression1,703
- pneumonitis900
- radiation pneumonitis812
- diarrhoea700
- pyrexia670
- off label use616
- pneumonia500
- dyspnoea495
- interstitial lung disease491
- fatigue484
- asthenia478
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 8 |
| 2017 | 168 |
| 2018 | 769 |
| 2019 | 1,362 |
| 2020 | 1,456 |
| 2021 | 1,718 |
| 2022 | 1,511 |
| 2023 | 2,836 |
| 2024 | 3,709 |
| 2025 | 4,001 |
| 2026 | 4,043 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Imfinzi (Durvalumab)
2024 spending
$26.3M
Beneficiaries
463
2,290 claims
Per beneficiary
$56,803
$407.60 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $8,125,802 |
| 2021 | $8,420,171 |
| 2022 | $12,360,160 |
| 2023 | $24,820,994 |
| 2024 | $26,299,907 |
Part B: Imfinzi (Durvalumab) · HCPCS J9173
2024 spending
$843M
Beneficiaries
14,791
79,678 claims
Per beneficiary
$56,999
2024 ASP limit $81.23 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $505,845,758 |
| 2021 | $453,544,572 |
| 2022 | $562,741,221 |
| 2023 | $738,581,821 |
| 2024 | $843,071,958 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Perioperative Durvalumab in Gastric and Gastroesophageal Junction Cancer.
Janjigian YY, Al-Batran SE, Wainberg ZA, et al. · N Engl J Med 2025 · Randomized Controlled Trial, Clinical Trial, Phase III
- Durvalumab Plus Carboplatin/Paclitaxel Followed by Maintenance Durvalumab With or Without Olaparib as First-Line Treatment for Advanced Endometrial Cancer: The Phase III DUO-E Trial.
Westin SN, Moore K, Chon HS, et al. · J Clin Oncol 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Perioperative Durvalumab with Neoadjuvant Chemotherapy in Operable Bladder Cancer.
Powles T, Catto JWF, Galsky MD, et al. · N Engl J Med 2024 · Clinical Trial, Phase III, Randomized Controlled Trial
- Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer.
Cheng Y, Spigel DR, Cho BC, et al. · N Engl J Med 2024 · Randomized Controlled Trial, Clinical Trial, Phase III
- Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer.
Oh DY, Ruth He A, Qin S, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
- Tremelimumab plus Durvalumab in Unresectable Hepatocellular Carcinoma.
Abou-Alfa GK, Lau G, Kudo M, et al. · NEJM Evid 2022 · Randomized Controlled Trial, Clinical Trial, Phase III
Sponsor: AstraZeneca
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.